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Abstract: To investigate the clinical efficacy and safety of ethylamine iodine in the treatment of malignant arrhythmia
after acute myocardial infarction. Method: 35 patients with malignant arrhythmia after acute myocardial infarction
were enrolled in our hospital from May 2013 to August 2014. The patients were treated with ethidium iodide load
of 75-150 mg/times. The patients were treated with intravenous infusion of 0.5-1.0 mg/min micro pump at 15-20 min.
The clinical curative effect and the heart rate were analyzed at 15 min, 1, 2 and 24 h after treatment respectively, mean
arterial pressure changes and adverse reactions and so on. Results: The total effective rate was 91.43% in the clinical
treatment. The heart rate, mean arterial pressure and the difference before treatment were significant (P <0.05) at 15 min,
1, 2, and 24 h after treatment and the drug dose was adjusted in 3 patients after bradycardia after return to the normal
range. Conclusion: Ethylamine iodine can be used in the clinical treatment of acute myocardial infarction and
malignant arrhythmia. It can achieve significant clinical curative effect, high safety and mild adverse reaction. It is
worthy to be popularized and applied.
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Introduction
In recent years, the prevalence of acute myocardial infarction gradually increased, after its occurrence often associated
with malignant rapid arrhythmia, is a critical clinical and critical disease [1]. At present, the clinical selection of
ethylamine iodine as antiarrhythmic treatment drugs, can effectively prevent the phenomenon of potassium outflow, to
promote the action potential time limit increases, but also can prevent calcium outflow, in the β receptor to play
non-competitive Inhibitory effect. In present time, ethylamine iodine is a drug that is clinically effective in the treatment
of antiarrhythmic drugs with a negative inotropic effect and is less potent. In this study, 35 patients with acute
myocardial infarction with malignant arrhythmia in patients with clinical treatment of ethylamine iodine given to the
treatment of its application to be analyzed, the specific content is as follows.
1. Materials and method
1.1 General information
The study was conducted in 35 patients with malignant arrhythmia after acute myocardial infarction in our hospital
from May 2013 to August 2014. Among them, 20 were male and 15 were female and 41-78 were the between the
average age (59.5 ± 6.2). All patients with disease diagnosis and the Chinese Medical Association in 2001 to develop
the relevant standards. Heart function NYHA classification: grade 5 patients;Ⅱ grade 15 patients,Ⅲ grade 10 patients,
Ⅳ grade 5 patients; infarct site: 15 cases of anterior wall, 5 cases of inferior wall, 8 cases of anterior wall and lower
wall, 3 cases of inferior wall and posterior wall, 4 cases of inferior wall and right ventricle; Arrhythmia type: 10 patients
with short-term atrial fibrillation accompanied by frequent ventricular contraction; 20 patients with paroxysmal
20 | Lu JZ. Advanced Emergency Medicine
ventricular tachycardia; 5 patients with ventricular fibrillation, all patients with arrhythmia seizures showed a more
obvious blood pressure reduction, serum potassium was (3.8 ± 0. 3) mmol / L. All patients voluntarily participated in
the study and signed informed consent.
1.1.1 Exclusion criteria [2]
① The presence of iodine, receptor blockers allergy history; ② Suffering from liver, kidney and other physical organ
dysfunction and electrolyte imbalance and other diseases; ③ Suffering from sinus node syndrome; ④ Ⅱ degree or
above the atrioventricular block;⑤ Suffering from mental illness and prolonged use of sedative drugs.
1.2 Method
All patients who were hospitalized were treated with ethylamine iodine and when the arrhythmia was or after
defibrillation, the patient was given intravenous injection of 75-150 mg of ethylamine iodofenone injection (Sanofi
Winthrop Industrie, National Pharmaceutical Serial Number J20070056), after 15-20min after adjusting the dose to
0.5-1.0mg / min speed continued continuous injection therapy. For arrhythmia still no change, you can every 30min and
then given patients with ethidium iodide baclitaxel 75-150 mg intravenous injection, if sustained within 24 h no
arrhythmia deterioration phenomenon, that can be discontinued observation. Eight patients were treated with
dobutamine, dopamine and other drugs due to heart failure, and the dose of ethylamine iodine was not changed. In the
course of the whole medication, all patients were given multi-functional ECG monitor on blood pressure, heart rate and
other indicators of continuous monitoring, while 15 min after treatment, 1,2,24 h heart rate, mean arterial pressure
changes and adverse reactions situation to observe.
1.3 Observe indicators
The clinical curative effect was observed. The changes of heart rate, mean arterial pressure and curative effect and
adverse reaction were observed at 15 min, 1, 2 and 24 h after treatment.
Disease clinical efficacy criteria [3]: ① Remarkably effective: The clinical symptoms were significantly improved,
ventricular arrhythmia disappeared, or ventricular premature beats and the frequency of treatment before the reduction
of more than 90%, arrhythmia converted to sinus; ② Effective: The patient's clinical symptoms have been reduced,
significantly slower heart rate. The incidence of ventricular arrhythmia was lower than that of the previous day, and the
number of ventricular premature beats was lower than that of the control group (P <0.05). ③ Invalid: The patient had
no change in the condition, the time of arrhythmia was changed, gradually increased. The total effective rate is
(significant number of cases + valid cases) / total number of cases * 100%.
1.4 Statistical analysis
All the data in the study were analyzed by SPSS18.0 statistical software. The count data were expressed as "n (%)". The
test was performed by x2 test. The data were expressed as "mean ± standard deviation", and the t test method validation.
If P <0.05, it means that there is statistical significance.
2.Results
2.1 To observe the different types of patients with arrhythmia clinical treatment
All patients were treated with sinus rhythm for ventricular fibrillation (84.7 ± 17.5) times/min; using amiodarone time
(36.3 ± 6.5) h, the dose was (213.0% 65.1) mg in 5 cases of ventricular fibrillation effective in 5 cases, ineffective in 2
cases; short-term atrial fibrillation and frequent ventricular premature astigmatism markedly effective in 8 cases,
effective in 11 cases, ineffective in 1 case, the total effective rate was 91.43%.
2.2 Observation and treatment after 15 min, 1,2,24 h heart rate and mean arterial pressure
changes
Compared with before treatment, the heart rate and average arterial pressure were improved at 15 min, 1, 2 and 24 h
after treatment, and the difference was statistically significant (P <0.05).
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Table 1 analysis of 15 minutes after treatment, 1,2,24 h heart rate and mean arterial pressure changes
Group Before treatment
After treatment
15min 1h 2h 24h
Heart rate/
（times/min）
138.8±28.4 105.4±11.8 89.6±15.8 89.6±15.8 72.5±14.0
Mean arterial
pressure/（mmhg）
48.2±9.6 60.2±10.2 72.6±10.8 83.8±9.0 89.5±9.6
2.3 To observe the occurrence of adverse reactions in patients
In the course of the whole treatment did not occur QT interval prolongation, cardiac function deterioration, ventricular
arrhythmia increased; 3 cases of slower heart rate in patients with reduced dose of heart rate gradually returned to
normal range.
3.Discussion
Acute myocardial infarction in Europe and the United States is the most common, about 1.5 million per year suffering
from myocardial infarction. In recent years, the incidence of the disease in the country gradually increased. The
pathogenesis is due to acute coronary artery disease, persistent ischemia, hypoxia caused by myocardial necrosis
symptoms, patients often show sternal after severe, persistent pain, accompanied by increased serum myocardial activity,
ECG and other symptoms , and can be combined with arrhythmia, heart failure and other complications, a serious threat
to the lives of patients [4]. In clinical diagnosis, due to the characteristics of occult disease in acute myocardial infarction
and do not have specific causes of increased mortality in patients, especially in patients with malignant arrhythmia.
Therefore, should be given timely and effective drug treatment, improve clinical efficacy and improve the prognosis.
With the continuous development of science and technology and medical equipment and the level of continuous
improvement and improvement, making coronary intervention is widely used, thereby enhancing the success rate of
acute cardiac infarction rescue, but with malignant arrhythmia symptoms, especially acute myocardial ventricular
fibrillation after infarction and ventricular tachycardia has gradually become the main cause of death [5]. There
have been relevant studies reported that malignant ventricular arrhythmias generally occur in the myocardial infarction
after a few hours, the incidence of 53.64% [6]. After acute myocardial infarction with malignant arrhythmia pathogenesis,
including the following: ① Due to the patient's myocardial cells in the ischemic, necrotic state, resulting in local
myocardial electrophysiological changes in the structure, so that the cardiomyocyte membrane Na+, K+ ion pump
dysfunction and trigger activities, and ultimately lead to myocardial cell activity that is difficult to maintain a balance
and directly lead to malignant arrhythmia; ② Myocardial ischemia, necrosis caused by the accumulation of
metabolites in vivo, metabolic acid-base balance disorders, catecholamine secretion increased and hypoxemia and other
phenomena , and thus indirectly caused by arrhythmia; ③ Patients with autonomic nervous system activity than
ever before, myocardial ischemia to promote endogenous catecholamines in the body and the sympathetic nervous
system is highly activated, prone to malignant arrhythmia; ④ Patients with acute myocardial infarction its ischemic,
hypoxia and cardiac output decreased, left ventricular pressure, increased capacity caused by increased ventricular wall
tension, the impact of myocardial electrophysiological characteristics, making ventricular fibrillation threshold
decreased and induced malignant ventricular arrhythmias [7].
In the clinical mechanism of malignant arrhythmia, given the type of disease patients with reasonable and scientific
antiarrhythmic drugs to improve the prognosis has an important positive effect. Ethylamine iodine is a complex
antiarrhythmic drug with all four classes of Vaughn Williams antiarrhythmic drugs. It has a more complex
electrophysiological effect and can effectively inhibit the production of sodium channels and calcium channels in
patients. APD, BRP extension, while the o-phase rise rate of a significant decline [8]. In addition, it can block the
sympathetic β receptor and α receptor and make the heart rate slow, dilate the characteristics of vascular smooth muscle.
Ethylamine iodine has an inhibitory effect on the patients' reflexive agglutination, which can promote the prolongation
of effective refractory period, inhibit the autonomy of sinus node and significantly reduce the peripheral blood
resistance, increase the coronary blood flow and reduce the patient's myocardial oxygen consumption and reduce
ventricular rate, fully to achieve the purpose of treatment of arrhythmia.
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It has been suggested that the use of ethylamine iodine in the treatment of patients with acute myocardial infarction
with malignant ventricular arrhythmias can reduce the mortality of arrhythmias in patients with myocardial infarction.
Compared with other drugs, amiodarone can help patients achieve the desired clinical efficacy and prognosis [9]. The
results of this study found that ethylamine iodine treatment of acute myocardial infarction after malignant ventricular
arrhythmia clinical effect is more significant, can effectively reduce the risk of cardiac death, ventricular arrhythmias. It
can be seen that ethylamine iodine is clinically effective in preventing ventricular tachycardia, ventricular fibrillation
occurred in the first wash drug. However, due to the traditional ethylamine iodine oral treatment with slow absorption,
long half-life defects and make the drug slow, for patients with malignant tachyarrhythmias in patients with unstable
hemodynamics clinical treatment is difficult to achieve the desired results. In addition, it was suggested that
administration of intravenous injection of ethylamine iodine injection in patients could reduce the risk of recurrence in
patients after cardioversion. In this study, 35 cases of acute myocardial infarction after the malignant arrhythmia to give
ethylamine iodine load, prompting the patient's myocardial tissue in the higher plasma concentration can be fully
exposed, through the use of micro-pump to effectively maintain the plasma concentration, to promote the plasma
concentration is always at the peak and the fastest speed to achieve effective blood concentration, on the other hand to
ensure that the plasma concentration of sustained and stable, the maintenance of sinus rhythm have a positive effect.
The results showed that the total effective rate of amiodarone was 91.43%, 15 min after treatment, 1, 2, 24 h heart rate
and mean arterial pressure before and after treatment, the difference was significant (p < 0.05), indicating that the way
through the micro-pump in patients with arrhythmia after acute myocardial infarction intravenous injection of
ethylamine iodine clinical efficacy is good, and no inhibition of cardiac pump function; when the malignant arrhythmia
has improved, still continued intravenous 24 h after injection, can reduce the recurrence rate of arrhythmia.
Studies have suggested that ethylamine iodine caused to low blood pressure and its lysing enzyme in a certain
relationship, to promote the slow pace of intravenous injection and reduce hypotension [11]. In the course of this study,
no symptoms of hypotension were observed in all patients. This may be related to the treatment of micro pumps. In the
intravenous use of ethylamine iodine treatment, should follow the principle of individual medication, help to reduce the
incidence of adverse reactions. 3 patients in the study of bradycardia occurred in the adjustment of drug dose can be
returned to their normal level.
In summary, the use of ethylamine iodine in the treatment of acute myocardial infarction after malignant
arrhythmia can be significantly improve the clinical efficacy and the prognosis, it is worth applying.
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